MNPR
HEALTHCAREMonopar Therapeutics Inc
AI Insight
What's Moving MNPR Today?
No stock-specific AI insight has been generated for MNPR yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$29.18$105.00
$81.77
Fundamentals
Market Cap$460M
P/E Ratio—
EPS$-1.93
Dividend Yield—
Dividend / Share—
ROE-15.9%
Profit Margin—
Debt / Equity—
Trading
Volume278K
Avg Volume (10D)—
Shares Outstanding6.7M
MNPR News
23 articles- Wall Street Analysts Believe Monopar Therapeutics (MNPR) Could Rally 88.92%: Here's is How to TradeYahoo Finance·Jun 15, 2026
- Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026Yahoo Finance·Jun 1, 2026
- Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson DiseaseYahoo Finance·May 19, 2026
- Monopar (NASDAQ: MNPR) ends Q1 with $137.5M cash and funds through 2027Stock Titan·May 14, 2026
- Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdatesYahoo Finance·May 14, 2026
- Biotech Monopar readies Wilson disease drug filing, funded into 2027Stock Titan·May 14, 2026
- Cash runway to 2027 as Monopar (NASDAQ: MNPR) readies ALXN1840Stock Titan·May 14, 2026
- Monopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth PlansYahoo Finance·May 3, 2026
- Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026Yahoo Finance·Apr 19, 2026
- Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business UpdateGlobeNewswire Inc.·Mar 27, 2026
- Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy OfficerYahoo Finance·Mar 2, 2026
- Institutional investors in Monopar Therapeutics Inc. (NASDAQ:MNPR) see US$66m decrease in market cap last week, although long-term gains have benefitted them.Yahoo Finance·Feb 11, 2026
- Broadcom Stock Sees Improved Relative Strength RatingYahoo Finance·Feb 9, 2026
- What Awaits These 4 Biotech Stocks That More Than Doubled in 2025Yahoo Finance·Dec 22, 2025
- Is Monopar Therapeutics Inc. (NASDAQ:MNPR) Trading At A 46% Discount?Yahoo Finance·Nov 22, 2025
- Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent DevelopmentsYahoo Finance·Nov 13, 2025
- Coinbase upgraded, Six Flags downgraded: Wall Street's top analyst callsYahoo Finance·Nov 10, 2025
- Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025Yahoo Finance·Nov 9, 2025
- Does Monopar Therapeutics (MNPR) Have the Potential to Rally 42.46% as Wall Street Analysts Expect?Yahoo Finance·Oct 21, 2025
- How the Narrative Around AstraZeneca Is Shifting Amid New Risks and Pipeline DevelopmentsYahoo Finance·Oct 18, 2025
- Raymond James Boosts Monopar Therapeutics (MNPR) PT to $142, Maintains Strong BuyYahoo Finance·Oct 16, 2025
- Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025Yahoo Finance·Oct 15, 2025
- Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsYahoo Finance·Sep 24, 2025
All 23 articles loaded
Price Data
Open$68.21
Previous Close$68.66
Day High$83.57
Day Low$68.21
52 Week High$105.00
52 Week Low$29.18
52-Week Range
$29.18$105.00
$81.77
Fundamentals
Market Cap$460M
P/E Ratio—
EPS$-1.93
Dividend Yield—
Dividend / Share—
ROE-15.9%
Profit Margin—
Debt / Equity—
Trading
Volume278K
Avg Volume (10D)—
Shares Outstanding6.7M
About Monopar Therapeutics Inc
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, is dedicated to developing proprietary therapies to improve clinical outcomes for cancer patients in the United States. The company is headquartered in Wilmette, Illinois.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—